2022 Seattle Multidisciplinary Thoracic Oncology Conference

Seattle, WA US
October 22, 2022

This oncology conference titled,  “2022 Seattle Multidisciplinary Thoracic Oncology Conference," is an accredited continuing education activity that features lectures and discussions presented by leading experts in thoracic cancers who will provide a comprehensive overview of recent advances and controversies in the management of thoracic cancers.

The goal of this continuing education activity is to improve the knowledge, competence and performance of learners so that they can apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with thoracic cancers. 

Target Audience

  • Oncologists
  • Oncology fellows
  • Oncology nurses
  • Oncology nurse practitioners
  • Oncology physician assistants
  • Oncology pharmacists

 

Learning Objectives

  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in standards of care in thoracic cancers
  • Compare and contrast the safety and efficacy profiles of novel therapeutic strategies that impact management of patients with thoracic cancers
  • Integrate emerging evidence into treatment paradigms for treatment of thoracic cancers.

You may also be interested in

Webcast - Seattle Multidisciplinary Lung Cancer Conference

This accredited continuing education activity “Seattle Multidisciplinary Lung Cancer Conference," is recorded from the live oncology conference held on 10/23/2021 at the Crowne Plaza Downtown Seattle. 
Course summary
Available credit: 
  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Course opens: 
03/04/2022
Course expires: 
10/22/2022
Event starts: 
10/22/2022 - 8:00am PDT
Event ends: 
10/22/2022 - 5:00pm PDT
Cost:
$200.00
Add to calendar: 

07:00 AM to 08:00 AM PST: Registration/Exhibition

08:00 AM to 08:10 AM PST: Welcome and opening remarks

08:10 AM to 10:00 AM PST:  Early stage non-small cell lung cancer

Moderator: Dr. Christina Baik

08:10 AM – 08:30 AM PST: Successes and challenges of lung cancer screening in 2022 - Dr. Jed Gorden

08:30 AM – 08:50 AM PST: Management of early stage lung cancer – new surgical approaches - Dr. Eric Vallieres

08:50 AM – 09:10 AM PST: Emerging data for radiation in early stage NSCLC - Dr. John Kang

09:10 AM – 09:30 AM PST: Systemic therapy in resectable NSCLC - Dr. Jack West

09:30 AM – 10:00 AM PST: Case-based discussion - Session speakers + Dr. Andrea Veatch

10:00 AM to 10:30 AM PST: Break/Exhibits 

10:30 AM to 12:00 PM PST: Molecular testing/targeted therapy in lung cancer

Moderator: Dr. Joseph Rosales 

10:30 AM – 10:50 AM PST: Current standards and open questions in unresectable NSCLC - Dr. Christina Baik

10:50 AM – 11:10 AM: Biomarker testing and current standards & barriers - Dr. Aakash Desai

11:10 AM - 11:30 AM: New targets and targeted therapies - Dr. Jonathan Riess

11:30 AM - 12:00 PM: Case-based discussion - Session speakers

12:00 PM – 13:00 PM PST: Lunch/Exhibits

13:00 PM – 14:30 PM PST: Immunotherapy in non-small cell lung cancer

Moderator: Dr. Jack West

13:00 PM – 13:20 PM PST: Evolving practices in immunotherapy for advanced NSCLC - Dr. Lyudmila Bazhenova

13:20 PM – 13:40 PM PST: Vaccines and emerging immunotherapy approaches for NSCLC - Dr. Rachel Sanborn

13:40 PM – 14:00 PM PST: Oligometastatic disease and local consolidation therapy in NSCLC - Dr. Puneeth Iyengar

14:00 PM – 14:30 PM PST: Case-based Discussion - Session speakers + Dr. Somasundarum Subramaniam

14:30 PM – 15:40 PM PST: Small cell lung carcinoma

Moderator: Dr. Rafael Santana-Davila

14:30 PM – 14:50 PM: Developments in Systemic Therapy for SCLC (limited and extensive stage) - Dr. Rafael Santana-Davila

14:50 PM – 15:10 PM: Developments in Local Therapy for SCLC (limited and extensive stage) - Dr. Arya Amini 

15:10 PM – 15:40 PM: Case-based discussion - Session speakers + Dr. Daniel Moore

15:40 PM - 15:50 PM: Closing remarks

15:50 PM PST: Adjourn

Grand Hyatt Seattle
721 Pine St.
Seattle, WA 98101
United States

A limited number of rooms have been reserved for the attendees of this conference at the Grand Hyatt Seattle at the discounted rate of $219 per night. All reservations must be made by September 30th to receive the discounted rate. Please go to the link below to reserve your room:

https://www.hyatt.com/en-US/group-booking/SEAGH/G-BOCT

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Moderator(s)

Christina Baik, MD MPH

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Turning Point;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Guardant;.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Rafael Santana-Davila, MD

has no relevant financial relationships to disclose at this time.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.
Speaker(s)

Arya Amini, MD

has no relevant financial relationships to disclose at this time.

Christina Baik, MD MPH

has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Guardant;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Turning Point;.
has a financial relationship (Grant Or Contract) with Takeda;.

Lyudmila Bazhenova

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Boehringher Ingelheim;.
has a financial relationship (Independent contractor) with Elevation Oncology;.
has a financial relationship (Independent contractor) with regeneron;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Intervenn;.
has a financial relationship (Independent contractor) with Novocure;.
has a financial relationship (Independent contractor) with Daichi;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Neuvogen;.
has a financial relationship (Independent contractor) with ORIC;.
has a financial relationship (Independent contractor) with Turning point;.
has a financial relationship (Independent contractor) with Merck;.

Aakash Desai, MBBS, MPH

has no relevant financial relationships to disclose at this time.

Puneeth Iyengar, MD, PhD

has a financial relationship (Other) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Employment) with UTSW;.

John Kang, MD, PhD

has a financial relationship (Employment) with Change Healthcare;.

Daniel Moore, MD MS

has no relevant financial relationships to disclose at this time.

Rachel Sanborn, M.D.

has a financial relationship (Independent contractor) with Sanofi Aventis;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Independent contractor) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with Macrogenics;.
has a financial relationship (Independent contractor) with GlaxoSmithKline;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with Mirati Therapeutics;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Lilly Oncology;.
has a financial relationship (Independent contractor) with Regeneron;.

Rafael Santana-Davila, MD

has no relevant financial relationships to disclose at this time.

Somasundaram Subramaniam, MD MS

has a financial relationship (Professional Services) with Exelixis;.

Eric Vallieres, MD, FRCS(C)

has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with Oncocyte;.
has a financial relationship (Other) with AstraZeneca;.

Andrea Veatch, MD

has no relevant financial relationships to disclose at this time.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Mirati;.

Acknowledgment of commercial support:

This activity has been supported with an independent Medical Education Grant from:

  • Pfizer

Available Credit

  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$200.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $200

Non-physician HPC (non-industry) - $125

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.